64 related articles for article (PubMed ID: 2384808)
1. Effects of propylthiouracil on the biodistribution of an iodine-131-labeled anti-myeloid antibody in normal dogs: dosimetry and clinical implications.
Bianco JA; Brown PA; Durack L; Badger C; Bernstein I; Eary J; Durham J; Fisher D; Sandmaier B; Schuening F
J Nucl Med; 1990 Aug; 31(8):1384-9. PubMed ID: 2384808
[TBL] [Abstract][Full Text] [Related]
2. Specific marrow localization of an 131I-labeled anti-myeloid antibody in normal dogs: effects of a "cold" antibody pretreatment dose on marrow localization.
Bianco JA; Sandmaier B; Brown PA; Badger C; Bernstein I; Eary J; Durack L; Schuening F; Storb R; Appelbaum F
Exp Hematol; 1989 Oct; 17(9):929-34. PubMed ID: 2776854
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131I.
Badger CC; Davis J; Nourigat C; Wu ZM; Hui TE; Fisher DR; Shulman H; Appelbaum FR; Eary JF; Krohn KA
Cancer Res; 1991 Nov; 51(21):5921-8. PubMed ID: 1682038
[TBL] [Abstract][Full Text] [Related]
4. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.
Matthews DC; Badger CC; Fisher DR; Hui TE; Nourigat C; Appelbaum FR; Martin PJ; Bernstein ID
Cancer Res; 1992 Mar; 52(5):1228-34. PubMed ID: 1531324
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.
Scheinberg DA; Lovett D; Divgi CR; Graham MC; Berman E; Pentlow K; Feirt N; Finn RD; Clarkson BD; Gee TS
J Clin Oncol; 1991 Mar; 9(3):478-90. PubMed ID: 1999719
[TBL] [Abstract][Full Text] [Related]
6. Use of iodine-131-labeled anti-immune response-associated monoclonal antibody as preparative regimen prior to bone marrow transplantation: initial dosimetry.
Appelbaum FR; Badger CC; Deeg HJ; Nelp WB; Storb R
NCI Monogr; 1987; (3):67-71. PubMed ID: 3547145
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model.
Nemecek ER; Hamlin DK; Fisher DR; Krohn KA; Pagel JM; Appelbaum FR; Press OW; Matthews DC
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):787-94. PubMed ID: 15701869
[TBL] [Abstract][Full Text] [Related]
8. 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis.
DeNardo GL; DeNardo SJ; Wessels BW; Kukis DL; Miyao N; Yuan A
Cancer Biother Radiopharm; 2000 Dec; 15(6):547-60. PubMed ID: 11190487
[TBL] [Abstract][Full Text] [Related]
9. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
11. Experimental radioimmunotherapy of murine lymphoma with 131I-labeled anti-T-cell antibodies.
Badger CC; Krohn KA; Shulman H; Flournoy N; Bernstein ID
Cancer Res; 1986 Dec; 46(12 Pt 1):6223-8. PubMed ID: 3779642
[TBL] [Abstract][Full Text] [Related]
12. High dose radiolabeled antibody therapy of lymphoma.
Bernstein ID; Eary JF; Badger CC; Press OW; Appelbaum FR; Martin PJ; Krohn KA; Nelp WB; Porter B; Fisher D
Cancer Res; 1990 Feb; 50(3 Suppl):1017s-1021s. PubMed ID: 2297714
[TBL] [Abstract][Full Text] [Related]
13. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody.
Siegel JA; Pawlyk DA; Lee RE; Sasso NL; Horowitz JA; Sharkey RM; Goldenberg DM
Cancer Res; 1990 Feb; 50(3 Suppl):1039s-1042s. PubMed ID: 2297717
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or F(ab')2 fragments.
Buchegger F; Chalandon Y; Pèlegrin A; Hardman N; Mach JP
J Nucl Med; 1991 Jul; 32(7):1414-21. PubMed ID: 2066798
[TBL] [Abstract][Full Text] [Related]
15. Dosimetry considerations of bone-seeking radionuclides for marrow ablation.
Bayouth JE; Macey DJ
Med Phys; 1993; 20(4):1089-96. PubMed ID: 8413017
[TBL] [Abstract][Full Text] [Related]
16. Antibody-radionuclide conjugates as part of a myeloablative preparative regimen for marrow transplantation.
Appelbaum FR; Brown P; Sandmaier B; Badger C; Schuening F; Graham T; Storb R
Blood; 1989 Jun; 73(8):2202-8. PubMed ID: 2659101
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
19. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
